NutriBand Inc.: Form 10-Q for the period ended Jul 31, 2023
Filed with the SEC on Sep 11, 2023 and accepted by EDGAR at Sep 8, 2023, 18:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-05-01 to 2023-07-31 | $655.9k | us-gaap:Revenues |
| Revenue | 6 months2023-02-01 to 2023-07-31 | $1.1m | us-gaap:Revenues |
| Cost of revenue | 3 months2023-05-01 to 2023-07-31 | $356.3k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-02-01 to 2023-07-31 | $610.9k | us-gaap:CostOfRevenue |
| Research and development | 3 months2023-05-01 to 2023-07-31 | $445.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-02-01 to 2023-07-31 | $845.6k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-05-01 to 2023-07-31 | $678.7k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-02-01 to 2023-07-31 | $1.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-05-01 to 2023-07-31 | −$824.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-02-01 to 2023-07-31 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-05-01 to 2023-07-31 | $9.2k | us-gaap:InterestExpense |
| Interest expense | 6 months2023-02-01 to 2023-07-31 | $12.4k | us-gaap:InterestExpense |
| Net income | 3 months2023-05-01 to 2023-07-31 | −$829.2k | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-02-01 to 2023-07-31 | −$1.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-05-01 to 2023-07-31 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-02-01 to 2023-07-31 | −$0.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-05-01 to 2023-07-31 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-02-01 to 2023-07-31 | −$0.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-05-01 to 2023-07-31 | 7,833,150 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-02-01 to 2023-07-31 | 7,833,150 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-02-01 to 2023-07-31 | −$1.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-02-01 to 2023-07-31 | $2.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-07-31 | $2.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-07-31 | $3.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-07-31 | $9.9m | us-gaap:Assets |
| Current liabilities | At period end2023-07-31 | $874.1k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-07-31 | $3.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-07-31 | $6.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-23-075508. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.